LAFAYETTE, La., July 19, 2017 -- LHC Group, Inc. (NASDAQ:LHCG) announced today details for the release of its results for the second quarter and six months ended June 30, 2017.
LHC Group plans to issue its earnings release for the second quarter ended June 30, 2017, after the market closes on Wednesday, August 2, 2017, and will host a conference call on Thursday, August 3, 2017, at 11:00 a.m. Eastern time. The toll-free number to call for this interactive teleconference is (866) 393-1608 (international callers should call (973) 890-8327). A telephonic replay of the conference call will be available through midnight on Thursday, August 10, 2017, by dialing (855) 859‑2056 (international callers should call (404) 537-3406) and entering confirmation number 40221056.
A live broadcast of LHC Group’s conference call will be available under the Investor Relations section of the Company’s website, www.LHCGroup.com. A one-year online replay will be available approximately an hour following the conclusion of the live broadcast.
About LHC Group, Inc.
LHC Group, Inc. is a national provider of non-acute healthcare services, providing quality, cost‑effective healthcare to patients primarily within the comfort and privacy of their home or place of residence. LHC Group provides a comprehensive array of healthcare services through home health, hospice, community-based services agencies and facility-based services. LHC Group operates 305 home health services locations, 73 hospice locations, 11 community-based service locations and six long-term acute care hospitals (LTACHs) with eight locations.
Certain matters discussed in this press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements about the Company’s future financial performance and the strength of the Company’s operations. Such forward-looking statements may be identified by words such as “continue,” “expect,” and similar expressions. Forward-looking statements involve a number of risks and uncertainties that may cause actual results to differ materially from those expressed or implied by such forward-looking statements, including changes in reimbursement, changes in government regulations, changes in LHC Group’s relationships with referral sources, increased competition for LHC Group’s services, increased competition for joint venture and acquisition candidates, changes in the interpretation of government regulations and other risks set forth in Item 1A. Risk Factors in LHC Group’s Annual Report on Form 10-K for the year ended December 31, 2016, filed with the Securities and Exchange Commission. LHC Group undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact: Eric Elliott Senior Vice President of Finance (337) 233-1307 [email protected]


Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 



